In this study, we have shown that LXRβ transcripts are overexpressed in breast tumors across all subtypes, and inhibition of LXR expression and activity by the novel inverse agonist 1E5 also potently inhibited the viability of tumor cells from luminal A and triple-negative breast cancers. This evidence concerns the gene NR1H2 and triple-negative breast carcinoma.